Ryan said that we do need better evidence around whether some individuals can maintain weight loss after coming off GLP-1s, but she thinks what Calibrate is doing is sharing the decision-making with the patient and trying to adapt to the environment where drugs may not always be available. Since Calibrate has come onto the market, results were published from a much larger, peer-reviewed study funded by the Ozempic manufacturer Novo Nordisk in 2022
Wiley, Hoboken, NJ, pp 209267 Gupta N, Sarkar S, David A, Gangwar PK, Gupta R, Khanna G, Sankhwar SN, Khanna A, Rajender S (2013) Significant impact of the MTHFR polymorphisms and haplotypes on male infertility risk
I used to get migraines when I was younger, but haven't had one for years
These efforts will be pivotal in advancing the precision and effectiveness of therapeutic interventions
Clinicians considering GLP-1 receptor agonists for post-bariatric weight regain typically conduct a comprehensive assessment to identify contributing factors